Table 5 Comparison of two reserve antimicrobial prices with what prices would need to be to achieve “fair share” in Germany.
From: Changes in revenues associated with antimicrobial reimbursement reforms in Germany
Current average annual revenue | Current median price per unit | Current median price per day of treatment | Current average annual sales volume (units) | What the price would need to be per unit to achieve “Fair Share,” assuming the same sales volume | Needed price multiplier | |
|---|---|---|---|---|---|---|
Avibactam/Ceftazidime | € 5,825,035 | € 130.72 | € 392.16 | 44,679 | € 429.17 | 3.3 |
Cefiderocol | € 5,820,612 | € 169.97 | € 1,019.82 | 35,407 | € 541.68 | 3.2 |
